Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5503 Target Snapshot

Nuclear receptor subfamily 1 group I member 3 · SINGLE PROTEIN · Homo sapiens

328Compounds
136Assays
3Approved Drugs
258.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q14994. Use UniProt Q14994 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q14994 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Nuclear receptor subfamily 1 group I member 3 as ChEMBL target CHEMBL5503, mapped to UniProt Q14994. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Nuclear receptor subfamily 1 group I member 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5503
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q14994
Nuclear receptor subfamily 1 group I member 3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Nuclear receptor subfamily 1 group I member 3 is the right protein anchor across sources, using UniProt Q14994 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNuclear receptor subfamily 1 group I member 3
UniProt AccessionQ14994
Component TypeProtein
Sequence Length352 aa

Nuclear receptor subfamily 1 group I member 3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Nuclear receptor subfamily 1 group I member 3, mapped to UniProt Q14994. Sequence length is 352 aa.

Mapped IDQ14994
Review nameNuclear receptor subfamily 1 group I member 3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

3
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC5068.0
KI1.0
EC50189.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5400735 9.0 EC50 1.0 Preclinical
CHEMBL5419791 9.0 EC50 1.0 Preclinical
CHEMBL5426747 9.0 EC50 1.0 Preclinical
CHEMBL5429867 9.0 EC50 1.0 Preclinical
CHEMBL5434244 9.0 EC50 1.0 Preclinical
CHEMBL5396305 8.7 EC50 2.0 Preclinical
CHEMBL5439022 8.7 EC50 2.0 Preclinical
CHEMBL5408637 8.52 EC50 3.0 Preclinical
CHEMBL5425742 8.4 EC50 4.0 Preclinical
CHEMBL458603 8.3 EC50 5.0 Preclinical
Distribution

pChEMBL Value Distribution

22
5.0
47
5.5
42
6.0
20
6.5
23
7.0
24
7.5
12
8.0
3
8.5
5
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

CLOTRIMAZOLE
CHEMBL104
Approved 1975
Assay Landscape

Assay Landscape

136
Total Assays
200
Tested Compounds
3
Assay Types
Binding — 104 assays, 200 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 87 95 6.0
single protein format 16 104 6.9
assay format 1 1 7.3
ADME — 26 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 20 0
single protein format 5 0
assay format 1 0
Functional — 6 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 5 2 6.7
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine